Novartis beat second-quarter profit expectations as Kisqali, Kesimpta and Leqvio offset a 50% plunge in Entresto sales. The Swiss drugmaker maintained its full-year guidance and awaits late-stage data on three experimental drugs.
Novartis has announced three separate partnership deals worth over $5 billion combined with Antares Therapeutics, Orionis Biosciences, and Unnatural Products. The agreements target undruggable cancers, molecular glue drugs, and cardiovascular therapies respectively using each partner's proprietary platforms.
Novartis will acquire Pikavation Therapeutics for up to $3 billion to gain its PI3Kα inhibitor programs, led by SNV4818 for metastatic breast cancer. The deal includes $2 billion upfront and up to $1 billion in milestones, with completion expected in first half 2026. SNV4818 is designed to selectively target mutated PI3Kα while sparing healthy cells.
